Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus

American Journal of the Medical Sciences

Volumn 325, Issue 2, 2003, Pages 66-69

  Bokhari, Syed U ^a   Gopal, Usha M ^a   Duckworth, William C ^a,b,c  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Glucose control; Glyburide metformin; Hemoglobin A1c; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; HEMOGLOBIN A1C; INSULIN;

ARTICLE; DRUG EFFICACY; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

EID: 0037329547     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200302000-00003     Document Type: Article

References (5)

1. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications 2002;16:123-32.
2. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7.
3. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of a combination glyburide/metformin tablet versus equivalent doses of glyburide plus metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002;41: 1301-9.
4. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-8.
5. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: The VA Diabetes Trial. Diabetes Care 2001;24:942-5.